Sleep Disorders

aarc zenith award 2020
Sleep Disorders

Dräger Honored with Ninth AARC Zenith Award

The American Association for Respiratory Care (AARC) honored Dräger as a recipient of this year’s Zenith Award during its 64th International Respiratory Conference in Las Vegas. This “people’s choice award” of the respiratory profession honors companies for their quality solutions, customer service and support. AARC members, which include 47,000 respiratory professionals […]

Insomnia Patient Health

Insomnia Workbook for Teens

Sleep is food for the brain – especially for teens. It’s hard being a teen in today’s fast-paced world. And it’s even harder to reach your goals when you’re feeling tired and run-down. Between early school start times, social media, electronic devices, extracurricular activities, and late-night homework—teens are at the highest […]

Pharmacological Industry News Narcolepsy

Promising Data for First New Narcolepsy Drug in Ten Years, Pending Approval

Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy Harmony Biosciences, LLC (Harmony) recently presented new data on pitolisant at the 7th International Symposium on Narcolepsy in Beverly, MA. Pitolisant is an investigational product that has […]

Radical-7 pulse oximetry masimo down syndrome
Research & Studies Sleep Apnea

New Study Investigates the Use of Home Monitoring to Screen Children with Down Syndrome for Risk of OSA Prior to Multichannel Sleep Studies

Masimo has announced the findings of a recently published study in which researchers investigated whether home pulse oximetry monitoring might be a useful initial screening method of determining which children with Down syndrome (DS) – who are at high risk of obstructive sleep apnea (OSA) – be recommended to undergo […]

orkambi for cystic fibrosis
Pediatric Health Pharmacological Sleep Disorders

FDA Approves ORKAMBI®, First Medicine to Treat the Underlying Cause of CF for Children Ages 2-5 Years with Most Common Form of the Disease

Vertex Pharmaceuticals Incorporated announced the U.S. Food and Drug Administration (FDA) has approved ORKAMBI® (lumacaftor/ivacaftor) to include use in children ages 2 through 5 years with cystic fibrosis (CF) who have two copies of the F508del-CFTR mutation, making it the first medicine approved to treat the underlying cause of CF […]

cannabis
Research & Studies Sleep Apnea

Clinical Trial for Treating OSA Using Cannabinoid-based Drug

Therapix Biosciences Ltd., a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced that on June 05, 2018, the first subject was enrolled for its Phase IIa, sponsor-initiated clinical trial using the Company’s cannabinoid-based technology THX-110 for Obstructive Sleep Apnea (OSA), at Assuta Medical Center, the largest […]